Vi flyttar från butik till nätet - så funkar det framåt
Benefit-Risk Assessment in Pharmaceutical Research and Development | 1:a upplagan
- Danskt band, Engelska, 2020
- Författare: Andreas Sashegyi, James Felli
- Betyg:
567
kr
Skickas inom 1-3 vardagar
Butikslager
Onlinelager
I lager hos leverantör
Fler utgåvor
-
Applied Meta-Analysis with R and Stata (2021)
2036 kr
-
Cure Models (2021)
995 kr
-
Bayesian Analysis of Infectious Diseases (2021)
1189 kr
-
Medical Risk Prediction Models (2021)
2261 kr
-
Confidence Intervals for Proportions and Related Measures of Effect Size (2020)
567 kr
-
Randomized Phase II Cancer Clinical Trials (2020)
567 kr
-
Bayesian Methods in Epidemiology (2020)
567 kr
-
Sample Size Calculations for Clustered and Longitudinal Outcomes in Clinical Research (2020)
504 kr
-
Inference Principles for Biostatisticians (2020)
567 kr
-
Medical Product Safety Evaluation (2020)
567 kr
-
Design and Analysis of Animal Studies in Pharmaceutical Development (2020)
567 kr
-
Measures of Interobserver Agreement and Reliability (2020)
567 kr
-
Randomized Clinical Trials of Nonpharmacological Treatments (2020)
567 kr
-
Controversial Statistical Issues in Clinical Trials (2020)
567 kr
-
Interval-Censored Time-to-Event Data (2020)
567 kr
-
Statistical Design and Analysis of Stability Studies (2020)
567 kr
-
Bayesian Methods for Measures of Agreement (2020)
567 kr
-
Clinical Trial Methodology (2020)
567 kr
-
Design and Analysis of Bridging Studies (2020)
567 kr
-
Design and Analysis of Non-Inferiority Trials (2020)
567 kr
-
Advanced Bayesian Methods for Medical Test Accuracy (2020)
567 kr
-
Bayesian Analysis Made Simple (2020)
567 kr
-
Quantitative Methods for HIV/AIDS Research (2020)
567 kr
Beskrivning
Many practitioners in the pharmaceutical industry are still largely unfamiliar with benefit-risk assessment, despite its growing prominence in drug development and commercialization. Helping to alleviate this knowledge gap, Benefit-Risk Assessment in Pharmaceutical Research and Development provides a succinct overview of the key considerations relevant to benefit-risk assessment across the pharmaceutical R&D spectrum, from early clinical development to late-stage development to regulatory review to post-launch assessment.
The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule’s journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies. The book also focuses on a molecule’s entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety.
Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
The book first presents interpretations of benefit and risk in the context of a molecule moving from preclinical evaluation into its early testing in humans. It next considers benefit and risk characterization and assessment during a molecule’s journey from its clinical evaluation in humans through its submission to regulators for marketing approval. Throughout these sections, the book offers insight into the role of benefit-risk assessment in heightening understanding among key stakeholders by shaping questions and guiding discussions among scientists, physicians, developers, and regulatory agencies. The book also focuses on a molecule’s entry into the marketplace as a drug available for consumption by people. It explores the role of benefit-risk assessment as the relevance of carefully collected clinical efficacy and safety metrics fades in the wake of real-world use and evidence of effectiveness and safety.
Bringing together the expertise of 15 contributors from academia and the industry, this book offers an easy-to-read guide to the various facets of benefit-risk assessment in the major stages of pharmaceutical R&D. Suitable for those in both technical and managerial roles, it enables readers to communicate more effectively across their development chain as well as rationally and thoughtfully embed benefit-risk assessment into their R&D processes.
Om denna bok
Benefit-Risk Assessment in Pharmaceutical Research and Development av Andreas Sashegyi och James Felli är en Danskt band bok med 220 sidor på Engelska. Detta är den 1:a upplagan som utgavs 2020.
Spara pengar – köp begagnad från Campusbokhandeln
Köp Benefit-Risk Assessment in Pharmaceutical Research and Development begagnad från Campusbokhandeln och spara upp till 25% jämfört med nypris. Du kan bevaka den här boken så får du ett mail så fort vi får in den i lager som begagnad.
Genom att köpa & sälja begagnat sänker du kostnaden för studier både för dig och nästa student samtidigt som du gör nytta för klimatet.
Produktinformation
Kategori:
Medicin, vård & fysiologi
Bandtyp:
Danskt band
Språk:
Engelska
ISBN:
9780367576240
Upplaga:
1
Utgiven:
2020-06-30
Förlag:
Okänt
Sidantal:
220